Terms: = Head and neck cancer AND PPFIBP1, L2, 8496, ENSG00000110841, hSGT2, hSgt2p AND Clinical Outcome
3 results:
1. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a cohort of 437 oesophageal cancers.
Okadome K; Baba Y; Nomoto D; Yagi T; Kalikawe R; Harada K; Hiyoshi Y; Nagai Y; Ishimoto T; Iwatsuki M; Iwagami S; Miyamoto Y; Yoshida N; Watanabe M; Komohara Y; Shono T; Sasaki Y; Baba H
Br J Cancer; 2020 May; 122(10):1535-1543. PubMed ID: 32210369
[TBL] [Abstract] [Full Text] [Related]
2. PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma.
Kogashiwa Y; Yasuda M; Sakurai H; Nakahira M; Sano Y; Gonda K; Ikeda T; Inoue H; Kuba K; Oba S; Ishikawa J; Enoki Y; Matsumura S; Minami K; Ebihara Y; Sugasawa M
Anticancer Res; 2017 Mar; 37(3):1417-1424. PubMed ID: 28314313
[TBL] [Abstract] [Full Text] [Related]
3. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis.
Horky LL; Hsiao EM; Weiss SE; Drappatz J; Gerbaudo VH
J Neurooncol; 2011 May; 103(1):137-46. PubMed ID: 20838854
[TBL] [Abstract] [Full Text] [Related]
